Skip to main content

Table 1 Background of 47 metastatic clear cell RCCs

From: Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy

  

1st line

2nd line (n = 41)

3rd line (n = 20)

IFN-alpha

IFN-alpha + sorafenib

Axitinib

CR/PR/SD > 24w (n = 6)

CR/PR/SD > 24w (n = 19)

SD < 24w/PD (n = 22)

CR/PR/SD > 24w (n = 9)

SD < 24w/PD (n = 11)

Sex (Male / Female)

32 / 15

     

Years (median)

39–78 (65)

     

ECOG PSa (0 / 1 / 2)

29 / 14 / 4

6 / 0 / 0

13 / 6 / 0

10 / 8 / 4

4 / 5 / 0

2 / 8 / 1

MSKCCa (Fav / Int / Poor)

24 / 15 / 8

6 / 0 / 0

9 / 7 / 0

9 / 8 / 8

2 / 7 / 0

1 / 8 / 2

Duration of IFN-alphaa (mean: months)

 

7–46 (15.9)

   

Duration of pre-IFN-alphaa (mean: months)

  

1–31 (7.4)

  

Duration of IFN-alpha + sorafenib (mean: months)

  

1–81 (19.7)

  

Duration of axitinib (mean: months)

    

1–37 (11.6)

Metastatic lesionsa (numbers)

 PUL

46

6

18

22

9

11

 PLE

6

1

2

3

2

2

 HEP

7

0

3

4

2

2

 OSSa

11

0

6

5

3

3

 LYM

12

0

6

6

3

4

 Others

3

0

0

3

0

2

  1. ECOG PSa: Eastern Cooperative Oncology Group (ECOG) performance status
  2. MSKCCa: Memorial Sloen-Kettering Cancer Center, Fav Favorable, Int Intermediated, Poor Poor risk
  3. Duration of IFN-alphaa: Duration of IFN-alpha monotherapy
  4. Duration of pre-IFN-alphaa: Duration of IFN-alpha monotherapy prior toIFN-alpha plus sorafenib
  5. Metastatic lesionsa; PUL Lung, PLE Pleura, HEP Liver, OSS Bone, LYM lymph node
  6. OSSa: Treatment option with Radiation plus Bisphosphonate or Denosmab